List of nationally authorised medicinal products
|
|
- Darlene Roberts
- 6 years ago
- Views:
Transcription
1 11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.
2 VAXEM Hib sospensione iniettabile in siringa preriempita Vaccino coniugato anti-haemophilus influenzae tipo b Хиберикс прах и разтворител за инжекционен разтвор Конюгатна ваксина срещу Haemophilus тип b Hiberix Polvere e solvente per soluzione iniettabile per uso intramuscolare Vaccino Haemophilus influenzae di tipo b coniugato al tossoide tetanico HIBERIX 10 μg/0,5 ml Pó e solvente para solução injetável. Vacina contra Haemophilus influenzae tipo b (Hib) HIBERIX - 10 microgrammes/0,5 ml Poudre et solvant pour solution injectable HIBERIX - 10 microgrammes/0,5 ml Poudre pour solution injectable Hiberix Wirkstoff: Haemophilusinfluenzae-b-Konjugat-Impfstoff HIBERIX Εμβόλιο Αιμόφιλου της ινφλουέντζας τύπου b (Hib) Hiberix. Haemophilus Type b (Hib) vaccine Powder and Solvent for Solution for Injection IT/H/0122/ GSK VACCINES S.R.L. IT not available GLAXOSMITHKLINE EOOD BG not available GLAXOSMITHKLINE S.P.A. IT not available BEECHAM PORTUGUESA- PT PRODUTOS FARMACEUTICOS E QUIMICOS, LDA not available BE GLAXOSMITHKLINE BE not available BE GLAXOSMITHKLINE BE not available 100A/95 GLAXOSMITHKLINE GMBH & CO. KG DE not available 40487/ GLAXOSMITHKLINE AEBE GR not available PA1077/027/001 GLAXOSMITHKLINE IE (IRELAND) LIMITED EMA/691535/2017 Page 2/8
3 Hiberix Vakcína proti Haemophilus influenzae typu b Prášek a rozpouštedlo pro injekcní roztok VAXEM Hib sospensione iniettabile in siringa preriempita Vaccino coniugato anti-haemophilus influenzae tipo b VAXEM Hib sospensione iniettabile Vaccino coniugato anti- Haemophilus influenzae tipo b HIBERIX Εμβόλιο Αιμόφιλου της ινφλουέντζας τύπου b (Hib) HIBERIX - 10 microgrammes/0.5ml Poudre et solvant pour solution injectable Hiberix, polvo y disolvente para solución inyectable. Vacuna conjugada Haemophilus influenzae tipo b Hiberix Polvere e solvente per soluzione iniettabile per uso intramuscolare Vaccino Haemophilus influenzae di tipo b coniugato al tossoide tetanico Hiberix Vaccine Haemophilus influenzae type b (Hib) vaccine Hiberix Vaccine Haemophilus influenzae type b (Hib) vaccine not available 59/1287/97-C GLAXOSMITHKLINE CZ IT/H/0122/ GSK VACCINES S.R.L. IT not available GSK VACCINES S.R.L. IT not available GLAXOSMITHKLINE CY not available GLAXOSMITHKLINE LU not available GLAXOSMITHKLINE, S.A. ES not available GLAXOSMITHKLINE S.P.A. IT not available PL 10592/0120 SMITHKLINE BEECHAM LTD UK not available MA 172/00401 SMITHKLINE BEECHAM PLC MT EMA/691535/2017 Page 3/8
4 Hiberix, poeder en oplosmiddel voor suspensie voor injectie Haemophilus Influenzae type b (Hib) vaccin HIBERIX 10 µg/0,5 ml Pó e solvente para solução injectável. Vacina contra Haemophilus influenzae tipo b (Hib) HIBERIX 10 µg/0,5 ml Pó e solvente para solução injectável Vacina contra Haemophilus influenzae tipo b (Hib) Hiberix, proszek i rozpuszczalnik do sporzadzania zawiesiny do wstrzykiwan. Vaccinum haemophili stirpe b coniugatum Szczepionka przeciwko zakazeniom haemophilus typ b, skoniugowana Act-HIB 10 microgrammes/0,5 ml, poudre et solvant pour solution injectable en seringue préremplie, Vaccin Haemophilus influenzae type b (conjugué) not available RVG GLAXOSMITHKLINE B.V. NL not available BEECHAM PORTUGUESA- PT PRODUTOS FARMACEUTICOS E QUIMICOS, LDA not available BEECHAM PORTUGUESA- PT PRODUTOS FARMACEUTICOS E QUIMICOS, LDA not available R/7048 GLAXOSMITHKLINE PL not available NL SANOFI PASTEUR SA FR EMA/691535/2017 Page 4/8
5 Act-HIB, 10 mikrogramów/0,5 ml, proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań Vaccinum haemophili stirpi b coniugatum Szczepionka przeciw haemophilus typ b, skoniugowana ACT-HIB 10 micrograms/0.5 ml, powder and solvent for solution for injection in a pre-filled syringe Haemophilus Influenzae type b vaccine (conjugated) ACT-HIB, 10 µg/0.5 ml, poudre et solvant pour solution injectable (IM, SC) en flacon multidose, Vaccin Haemophilus type b conjugué Act-HIB stungulyfsstofn og leysir, lausn Samtengt bóluefni gegn Haemophilus influenzae af stofni b Act-HIB 10 microgram/0,5 ml poeder en oplosmiddel voor oplossing voor injectie Geconjugeerd Haemophilus influenzae type b vaccin ACT-HIB Συνεζευγμένο εμβόλιο Haemophilus influenzae τύπου b not available R/3468 SANOFI PASTEUR SA PL not available SANOFI PASTEUR SA CY not available NL SANOFI PASTEUR SA FR not available SANOFI PASTEUR EUROPE IS not available RVG SANOFI PASTEUR EUROPE NL not available 60813/ & 63436/ SANOFI PASTEUR EUROPE GR 2016 EMA/691535/2017 Page 5/8
6 Act-HIB powder and solvent for solution for injection Haemophilus influenzae type b conjugate vaccine ACT-HIB Polvere e solvente per soluzione iniettabile Vaccino Haemophilus influenzae di tipo b coniugato al tossoide tetanico Act-HIB 10 µg/0,5 ml pó e solvente para solução injectável Vacina conjugada contra o Haemophilus influenzae tipo b (conjugada com proteína tetânica) Act-HIB powder and solvent for solution for injection Haemophilus influenzae type b conjugate vaccine ACT-HIB polvo y disolvente para solución inyectable. Vacuna de polisacárido de Haemophilus influenzae tipo b conjugado a proteína del tétanos Act-HIB 10 mikrogram/0,5 ml.pulver og væske til injeksjonsvæske, oppløsning Vaksine mot Haemophilus type b, konjugert Act-HIB, pulver og solvens til injektionsvæske, opløsning not available PL 46602/0011 SANOFI PASTEUR EUROPE UK not available SANOFI PASTEUR EUROPE IT not available SANOFI PASTEUR EUROPE PT not available PA 2131/001/001 SANOFI PASTEUR EUROPE IE not available SANOFI PASTEUR EUROPE ES not available 7985 SANOFI PASTEUR EUROPE NO not available SANOFI PASTEUR EUROPE DK EMA/691535/2017 Page 6/8
7 Act-HIB,10 mikrog/0,5 ml injektiokuiva-aine ja liuotin, liuosta varten Haemophilus influenzae tyyppi b (Hib) -rokote (konjugoitu) Act-HIB 10 mikrogram/0,5 ml pulver och vätska till injektionsvätska, lösning Haemophilus influenzae -vaccin, typ b (konjugerat) Act-HIB 10 µg/0,5 ml, Trockensubstanz und Lösungsmittel für Injektionslösungen Impfstoff Haemophilus influenzae Typ b (Konjugat) Act-HIB 10μg/0,5 ml, poudre et solvant pour solution injectable Vaccin Haemophilus influenzae type b (conjugué) Act-HIB Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension Act-HIB 10 microgram/0,5 ml, poeder en oplosmiddel voor oplossing voor injectie Geconjugeerd Haemophilus influenzae type b vaccin not available SANOFI PASTEUR EUROPE FI not available SANOFI PASTEUR EUROPE FI not available 0491/02/12/7082 SANOFI PASTEUR EUROPE LU not available 0491/02/12/7082 SANOFI PASTEUR EUROPE LU not available SANOFI PASTEUR EUROPE AT not available BE SANOFI PASTEUR EUROPE BE EMA/691535/2017 Page 7/8
8 Act-HIB 10 Mikrogramm/0,5 ml, Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Konjugatimpfstoff gegen Haemophilus influenzae Typ b Act-HIB 10 microgrammes/0,5 ml, poudre et solvant pour solution injectable Vaccin conjugué de l' Haemophilus influenzae type b Act-HIB pulver och vätska till injektionsvätska, lösning Vaccin mot Haemophilus influenzae typ b, konjugerat Act-HiB Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension Haemophilus Typ b-impfstoff (konjugiert) not available BE SANOFI PASTEUR EUROPE BE not available BE SANOFI PASTEUR EUROPE BE not available SANOFI PASTEUR EUROPE SE not available 482A/91 SANOFI PASTEUR EUROPE DE EMA/691535/2017 Page 8/8
List of nationally authorised medicinal products
12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30
More informationList of nationally authorised medicinal products
1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU
More informationList of nationally authorised medicinal products
28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30
More informationList of nationally authorised medicinal products
30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU
More informationANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES 1 Member State EU/EEA Marketing Authorisation Holder Austria
More informationList of nationally authorised medicinal products
12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605
More informationList of nationally authorised medicinal products
10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London
More informationList of nationally authorised medicinal products
21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711
More informationList of nationally authorised medicinal products
12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill
More informationList of nationally authorised medicinal products
8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary
More informationList of nationally authorised medicinal products
11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place
More informationList of nationally authorised medicinal products
10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus
More informationList of nationally authorised medicinal products
08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United
More informationList of nationally authorised medicinal products
06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20
More informationList of nationally authorised medicinal products
26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place
More informationV020 1 B. PACKAGE LEAFLET
V020 1 B. PACKAGE LEAFLET Package leaflet: Information for the patient Pantoprazole 40 mg powder for solution for injection pantoprazole sodium sesquihydrate Read all of this leaflet carefully before you
More informationList of nationally authorised medicinal products
29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationList of nationally authorised medicinal products
12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Secretine Iberoinvesa Pharma S.L. 100 E, poeder en oplosmiddel voor oplossing voor injectie/infusie
PACKAGE LEAFLET: INFORMATION FOR THE USER Secretine Iberoinvesa Pharma S.L. 100 E, poeder en oplosmiddel voor oplossing voor injectie/infusie Secretin pentahydrochloride Read all of this leaflet carefully
More informationList of nationally authorised medicinal products
13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf
More informationList of nationally authorised medicinal products
6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationList of nationally authorised medicinal products
12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationinjection injection injection injection injection injection injection
Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of administration, applicant in the Member States 1 Member State EU/EEA Applicant Name
More informationList of nationally authorised medicinal products
30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationV007 B. PACKAGE LEAFLET
B. PACKAGE LEAFLET Package leaflet: Information for the user Fyremadel 0.25 mg/0.5 ml solution for injection in pre-filled syringe ganirelix Read all of this leaflet carefully before you start using this
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion
PACKAGE LEAFLET: INFORMATION FOR THE USER ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using this medicine.
More informationList of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
More informationList of nationally authorised medicinal products
6 September 2018 EMA/612350/2018 Human Medicines Evaluation Division Active substance: azelastine Procedure no.: PSUSA/00000277/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. PEGLAX 10g Powder for oral solution in sachet. Macrogol 4000
PACKAGE LEAFLET: INFORMATION FOR THE USER PEGLAX 10g Powder for oral solution in sachet Macrogol 4000 Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationList of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationPackage leaflet: Information for the user. ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion
Package leaflet: Information for the user ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using
More informationEuropean Medicines Agency decision
EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for
More informationPackage leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin
Package leaflet: Information for the user Human anti-d immunoglobulin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this
More informationList of nationally authorised medicinal products
7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN)
PACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN) Read all of this leaflet carefully before you are given Oxaliplatin. - Keep this leaflet. You
More informationTadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung. Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation s in the member states 1 Austria Forest Pharma B.V. Newtonlaan
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
biosyn Arzneimittel GmbH Schorndorfer Strasse 32, 70734 Fellbach, Germany PACKAGE LEAFLET: INFORMATION FOR THE USER Selenase 100 micrograms, solution for injection (50 micrograms/ml) 100 microgram selenium
More informationPACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER. Prilotekal 20 mg/ml solution for injection prilocaine hydrochloride
Page 1 PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER Prilotekal 20 mg/ml solution for injection prilocaine hydrochloride Read all of this leaflet carefully before you are given this medicine
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
a Novartis Company PACKAGE LEAFLET: INFORMATION FOR THE USER Pantoprazole Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to read it again. -
More informationInitial (Full) Marketing Authorisation application accelerated assessment timetables
30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European
More informationEuropean Medicines Agency decision
EMA/501681/2016 European Medicines Agency decision P/0213/2016 of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA- 001214-PIP01-11-M05)
More informationEuropean Medicines Agency decision
EMA/279562/2017 European Medicines Agency decision P/0129/2017 of 8 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Split influenza virus, inactivated containing
More informationSupporting regulatory science outside the EU. The Article 58 procedure. An agency of the European Union
Supporting regulatory science outside the EU The Article 58 procedure An agency of the European Union What is the Article 58 procedure? EMA, through its scientific committees, can carry out scientific
More informationEuropean Medicines Agency decision
EMA/574564/2017 European Medicines Agency decision P/0278/2017 of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated,
More informationEuropean Medicines Agency decision
EMA/151867/2018 European Medicines Agency decision P/0107/2018 of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M07)
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Lidocaine Accord 10 mg/ml solution for injection Lidocaine Accord 20 mg/ml solution for injection Lidocaine hydrochloride Read all of this leaflet carefully before
More informationCHMP List of questions
28 June 2018 EMA/CHMP/346196/2018 To be addressed by the marketing authorisation holders for bacterial lysatescontaining medicinal products for respiratory conditions Referral under Article 31 of Directive
More informationList of nationally authorised medicinal products
12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationList of nationally authorised medicinal products
24 January 2018 EMA/270645/2015 Human Medicines Evaluation Division Active substance: azithromycin (systemic use formulations) Procedure no.: PSUSA/00010491/201704 30 Churchill Place Canary Wharf London
More informationVersion: 0005 February 2008 powder for solution for infusion Replaces: 0004 July 2007 PACKAGE LEAFLET: INFORMATION FOR THE USER
Page: 1 Package Leaflet PACKAGE LEAFLET: INFORMATION FOR THE USER powder for solution for infusion Oxaliplatin Read all of this leaflet carefully before you start using this
More informationList of nationally authorised medicinal products
28 September EMA/662335/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): levosalbutamol, salbutamol Procedure No.: PSUSA/00010330/201701 30
More informationPackage leaflet: Information for the patient. Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie
Package leaflet: Information for the patient Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie Landiolol hydrochloride This medicine is subject to additional
More informationPART I.B. Laboratoire TVM DIAZEPAM TVM / ZIAPAM, 5 MG/ML, SOLUTION FOR INJECTION FOR
PART I.B 1 TABLE OF CONTENT PART I.B: SPC, LABELLING AND PACKAGE INSERT Pages 1.b.1 Summary of product characteristics (SPC)... 3 1.b.2 Labelling and Package... 8 1.b.2.a Labelling... Unchanged 1.b.2.b
More informationEuropean Medicines Agency decision
EMA/501874/2008 European Medicines Agency decision P/0303/2016 of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/757980/2016 European Medicines Agency decision P/0313/2016 of 21 December 2016 on the agreement of a paediatric investigation plan for complex of povidone and iodine / dexamethasone (SHP640) (EMEA-001936-PIP01-16)
More informationEuropean Union herbal monograph on Pistacia lentiscus L., resin (mastix)
7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union
More information(DK/H/1774/001/R/001 Response on add CMS comments FRAR) OXALIPLATIN 150 MG; 50 MG POWDER FOR SOLUTION FOR INFUSION
Sandoz Business use only Page 1 of 10 Package leaflet: Information for the patient Oxaliplatin Ebewe 5mg/ml powder for solution for infusion Oxaliplatin Read all of this leaflet carefully before you are
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
31 May 2018 EMA/CHMP/258276/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Dabigatran etexilate, hard capsules, 75 mg, 110 mg and 150 mg productspecific bioequivalence
More informationEnsuring protection of public health and patients in member states: priorities, constraints, opportunities
Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria
More informationEuropean Union herbal monograph on Ruscus aculeatus L. rhizoma
30 January 2018 EMA/188804/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ruscus aculeatus L. rhizoma Draft Initial assessment Discussion in Working Party on European
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationEuropean Union herbal monograph on Eschscholzia californica Cham., herba
28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European
More informationImplementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO
Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'
More informationEuropean Medicines Agency decision
EMA/357972/2017 European Medicines Agency decision P/0173/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M05)
More informationPACKAGE LEAFLET: Information for the User
PACKAGE LEAFLET: Information for the User APO-go PEN 10mg/ml Solution for Injection * Apomorphine hydrochloride * Abbreviated to APO-go Pen in the text Read all of this leaflet carefully before you start
More informationList of nationally authorised medicinal products
26 October 2017 EMA/663700/2017 Human Medicines Evaluation Division Active substance: cromoglicic acid Procedure no.: PSUSA/00000883/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER NALOXONE 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using
More informationUpdate on public hearing
Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity
More informationPublic summary of opinion on orphan designation
9 February 2015 EMA/COMP/164684/2010 Rev.2 Committee for Orphan Medicinal Products Maytansinoid-conjugated humanised monoclonal antibody against CD56 for the treatment of cell carcinoma First publication
More informationPackage leaflet: Information for the user. Powder for concentrate for Solution for Infusion Ceftobiprolee
PACKAGE LEAFLET 1 Zevtera 500 mg Powder for concentrate for Solution for Infusion Ceftobiprolee Read all of this leaflet carefully before you start using this medicine because it contains important informationn
More informationEuropean Medicines Agency decision
EMA/731087/2017 European Medicines Agency decision P/0341/2017 of 16 November 2017 on the acceptance of a modification of an agreed paediatric investigation plan for influenza virus surface antigens (haemagglutinin
More informationEuropean Medicines Agency decision
EMA/761887/2015 European Medicines Agency decision P/0307/2015 of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for odanacatib (EMEA- 001123-PIP01-11-M03)
More informationEuropean Medicines Agency decision
EMA/75596/2018 European Medicines Agency decision P/0076/2018 of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationVARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014
Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack
More informationEuropean Medicines Agency decision
EMA/38339/2017 European Medicines Agency decision P/0021/2017 of 3 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA- 001501-PIP02-13-M02)
More informationPackage leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride
Package leaflet: Information for the user Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using this medicine because
More informationPublic summary of opinion on orphan designation
3 May 2017 EMA/143980/2017 Committee for Orphan Medicinal Products Poly-cyclodextrin-bis-cysteine-PEG 3400 -camptothecin-conjugate for the treatment of ovarian cancer On 20 March 2017, orphan designation
More information